(Q38014710)

27 August 2017

title

How should primary care doctors select which antidepressants to administer? (English)

1 reference

27 August 2017

1

1 reference

27 August 2017

4

1 reference

27 August 2017

Kylie Thaler

2

1 reference

27 August 2017

Seth Hill

series ordinal

3

1 reference

27 August 2017

language of work or name

English

0 references

publication date

1 August 2012

1 reference

Current Psychiatry Reports

27 August 2017

published in

1 reference

27 August 2017

volume

14

1 reference

27 August 2017

issue

4

1 reference

27 August 2017

page(s)

360-369

1 reference

Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

National patterns in antidepressant medication treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Determinants of direct cost differences among US employees with major depressive disorders using antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

A systematic review of newer pharmacotherapies for depression in adults: evidence report summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Efficacy, tolerability and side-effect profile of fluvoxamine for major depression: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Using meta-regression in performing indirect-comparisons: comparing escitalopram with venlafaxine XR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

21 January 2018

Ranking antidepressants.

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

21 January 2018

12 December 2020

A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Which factors influence psychiatrists' selection of antidepressants?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Predictors of alternative antidepressant agent initiation among U. S. veterans diagnosed with depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Duloxetine treatment of social anxiety disorder with comorbid major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Medication augmentation after the failure of SSRIs for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Treatment of dysthymia and minor depression in primary care: A randomized controlled trial in older adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Subthreshold depression as a risk indicator for major depressive disorder: a systematic review of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Hepatic adverse reactions associated with nefazodone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Hepatic effects of duloxetine-III: analysis of hepatic events using external data sources

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Suicide and self-harm following prescription of SSRIs and other antidepressants: confounding by indication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Expanding the black box - depression, antidepressants, and the risk of suicide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Antidepressants and the risk of suicidal behaviors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0283-X

Mirtazapine compared with paroxetine in major depression

21 January 2018

1 reference

12 December 2020

Risks of suicide and poisoning among elderly patients prescribed selective serotonin reuptake inhibitors: a retrospective cohort study.

1 reference

12 December 2020

Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group.

1 reference

12 December 2020

Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group

1 reference

12 December 2020

Minor depression: midway between major depression and euthymia

1 reference

12 December 2020

1 reference

12 December 2020

A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients.

1 reference

12 December 2020

Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder

1 reference

12 December 2020

Fluoxetine versus trazodone: efficacy and activating-sedating effects

1 reference

12 December 2020

Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and meta-analysis.

1 reference

12 December 2020

Citalopram versus sertraline in late-life nonmajor clinically significant depression: a 1-year follow-up clinical trial.

1 reference

12 December 2020

Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder

1 reference

12 December 2020

A double-blind study of long-term treatment with sertraline or fluvoxamine for prevention of highly recurrent unipolar depression

1 reference

12 December 2020

A comparison of venlafaxine, trazodone, and placebo in major depression.

1 reference

12 December 2020

A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial.

1 reference

12 December 2020

The economic burden of depression in the United States: how did it change between 1990 and 2000?

1 reference

12 December 2020

Double-blind comparison of bupropion and fluoxetine in depressed outpatients

1 reference

12 December 2020

Treatment of dysthymia with sertraline: a double-blind, placebo-controlled trial in dysthymic patients without major depression

1 reference

12 December 2020

Does randomized evidence support sertraline as first-line antidepressant for adults with acute major depression? A systematic review and meta-analysis.

1 reference

12 December 2020

Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression

1 reference

12 December 2020

Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association

1 reference

12 December 2020

Long-term treatment of depression

1 reference

12 December 2020

Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression

1 reference

12 December 2020

1 reference

12 December 2020

Controlled efficacy study of fluoxetine in dysthymia

1 reference

12 December 2020

Randomized, double-blind, placebo-controlled trial of fluoxetine treatment for elderly patients with dysthymic disorder.

1 reference

12 December 2020

Four-year follow-up study of sertraline and fluvoxamine in long-term treatment of unipolar subjects with high recurrence rate

1 reference

12 December 2020

Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms

1 reference

12 December 2020

Treatment of dysthymia and minor depression in primary care: a randomized trial in patients aged 18 to 59 years

1 reference

12 December 2020

Factors affecting prescribing of the newer antidepressants

1 reference

12 December 2020

Sexual function during bupropion or paroxetine treatment of major depressive disorder.

1 reference

12 December 2020

A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression

1 reference

12 December 2020

The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases.

1 reference

12 December 2020

Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group.

1 reference

12 December 2020

Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety

1 reference

12 December 2020

10.1007/S11920-012-0283-X

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1025004480

0 references

1 reference